Juva Research is Juva Life’s therapeutics division that has two primary initiatives. The first is to conduct the world’s largest patient study on the use of cannabis products and their effects on a variety of indications. The goal of the study is to create one of the largest data sets of its kind, establishing a “proof-of-concept” of the therapeutic potential of cannabis. The second initiative is for researchers at Juva to conduct clinical research on cannabis-based molecules and formulations proprietary to Juva, with the goal of identifying and proving their therapeutic potential.


As part of its IRB-approved longitudinal registry study, known as the JuLi Study, Juva is creating a collection of real-world data that is patient-reported and will identify clinical outcomes of the various effects of cannabis use on certain indications. 

Initial clinical indications being targeted include pain, sleep, appetite, among others. Data to be recorded includes:

  • Basic demographics of patients using cannabis-based medications.
  • Disease diagnoses and symptoms for which patients are seeking management.
  • Cannabinoid formulation, chemical composition, amount (in milligrams), dose and utilization.
  • Patient Reported Outcomes (PRO) for sleep, pain, appetite, and other indications.
  • Concomitant use of other anti-inflammatory or analgesic medications.

Using the data collected from this study, Juva will develop a wide range of pharmacy-grade cannabis products that are consistent, rigorously tested and meticulously formulated to address the needs of patients using cannabis for medical purposes.

This work is critical to make progress toward the development of new, safe and evidence-based cannabis products that target unmet medical needs.

The study is currently accepting applications. Click below to learn more and to see if you qualify for participation.

Learn More


Recently announced in 2021, Juva researchers have identified two non-cannabinoid, proprietary compounds that are found in the cannabis plant: JUVA-019 and JUVA-041. 

Prior to their identification, Juva has been developing a chemical library of natural and semi-synthetic non-cannabinoids found in the cannabis plant with the intention of identifying compounds with anti-inflammatory properties, with the first compound identified as JUVA-019. Juva’s hypothesis is that the therapeutic potential of cannabis is widely known, yet the cause of the overarching medical benefits of cannabis is mostly undefined. While many speculate that cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD) interacting with the endocannabinoid system are the cause of the benefit, Juva is taking a chemical approach to the research, looking further into the compounds present in the plant beyond cannabinoids that may have therapeutic benefit. As such, the Juva research team has built an extensive database of less studied compounds that it continues to evaluate for their anti-inflammatory potential, now having two compounds in its clinical pipeline: JUVA-019 and JUVA-041.

Both compounds have been designated as pre-lead compounds and have moved into the preclinical stage of research.


Juva Life is transforming personal health and opening a world of opportunities. Get connected to stay at the leading edge of an emerging marketplace.